Medical news

Menopause Services during COVID-19 – patient survey

As a result of the Covid 19 pandemic, many menopause services have changed their service provision to either telephone or video consultations where appropriate in order to offer alternatives to face to face appointments thereby helping to minimise patients’ hospital visits. The British Menopause Society (BMS) would like to find out more about your experience [...]

2020-12-01T13:20:09+00:001 December 2020|

Menopause Services during COVID-19 – clinician survey

As a result of the Covid 19 pandemic, many menopause services have changed their service provision to either telephone or video consultations where appropriate in order to offer alternatives to face to face appointments thereby helping to minimise patients’ hospital visits. The British Menopause Society (BMS) would like to find out more about your views [...]

2020-12-01T13:32:34+00:001 December 2020|

Reflections and recommendations on the COVID-19 pandemic: Should hormone therapy be discontinued?

Cagnacci,a,* G. Bonaccorsi,b M. Gambacciani,c and the board of the Italian Menopause Society have provided advice on the use of hormone therapy during the Covid 19 pandemic. On reviewing available evidence, they have concluded that while a recommendation for COVID-19-positive individuals to stop hormone therapy or oral contraceptives may seem wise, it is not based on real data. [...]

2020-10-05T12:08:29+01:005 October 2020|

British Menopause Society further update on HRT supply shortages (28 September 2020)

The British Menopause Society has issued this further update on the current availability of HRT products to provide guidance to BMS members and clinical practitioners in response to the ongoing HRT shortages. The British Menopause Society has issued this further update on the current availability of HRT products to provide guidance to BMS members and [...]

2020-09-28T12:37:02+01:0028 September 2020|

HRT and breast cancer statement in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020

This is an updated Joint BMS, IMS, EMAS, RCOG and AMS Position Statement on HRT and breast cancer risk and includes a summary of the evidence on dydrogesterone. We are aware that the statement is likely to be used by healthcare professionals to guide clinical practice and we believe this additional information would be of [...]

2020-09-14T12:15:48+01:0014 September 2020|

BMS, IMS, EMAS, RCOG and AMS Joint Statement

A joint statement has been issued by the British Menopause Society, the International Menopause Society, the European Menopause and Andropause Society, the Royal College of Obstetricians and Gynaecologists and the Australasian Menopause Society on menopausal hormone therapy (MHT) and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020.

2020-08-18T09:37:16+01:0018 August 2020|
Go to Top